Quantcast

Latest Chemokine Stories

2010-05-19 09:49:00

MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., the Company's President and Chief Executive Officer is a finalist for the Ernst & Young Entrepreneur Of The Year® 2010 Award in Northern California. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their...

2010-04-08 07:30:00

MOUNTAIN VIEW, Calif., April 8 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified a novel orally available small molecule antagonist of the ChemR23 chemoattractant receptor, CCX832, for clinical development. CCX832 represents the fourth and final drug candidate under the Company's alliance with GlaxoSmithKline (NYSE: GSK), whose acceptance of which, triggered a $5 million milestone payment. CCX832 is designed to target the chemoattractant ChemR23 receptor believed...

2010-03-22 07:30:00

MOUNTAIN VIEW, Calif., March 22 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2. This receptor has been shown to play a role in the inflammatory response associated with metabolic diseases including type 2 diabetes, as well as other diseases including vascular restenosis following stent placement, and...

2010-01-28 07:30:00

MOUNTAIN VIEW, Calif., Jan. 28 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases. CCX168 is a highly potent and very selective compound that specifically targets the C5a receptor (C5aR), a component of the body's complement system and a potent driver of the inflammatory response associated with autoimmune diseases such as systemic lupus erythematosus, certain...

2010-01-12 07:00:00

MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire/ -- ChemoCentryx, Inc., announced today that the Company has appointed Geoffrey M. Parker to the Company's Board of Directors, effective immediately. Mr. Parker is Chief Business Officer of InteKrin Therapeutics, Inc. and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. From 1997 to 2009, Mr. Parker directed Goldman Sachs' West Region Healthcare Investment Banking practice, advising...

2010-01-06 07:30:00

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire/ -- ChemoCentryx, Inc., today announced that the executive management team will participate in the 28th Annual J.P. Morgan Healthcare Conference being held January 11 through January 14 in San Francisco at the Westin St. Francis Hotel. Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, is scheduled to present an update of the company's pipeline progress and recent developments on Tuesday, January 12, 2010 at 4:30 p.m....

2009-12-16 07:30:00

MOUNTAIN VIEW, Calif., Dec. 16 /PRNewswire/ -- ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA). CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of immune cells, such as monocytes and macrophages, associated...

2009-07-08 17:39:00

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time. "It...

2009-06-15 10:09:24

Up-regulation of certain cytokines and chemokines (signaling molecules involved in the functioning of the immune system) can predict the development of rheumatoid arthritis (RA) three years before the onset of symptoms, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.The results of the study showed that up-regulation of certain cytokines (specifically Th1, Th2 and Treg) involved in the...

2009-05-05 07:30:00

Development Candidate Triggers Milestone Payment from GlaxoSmithKline MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally bioavailable small molecule antagonist of the C5a receptor, CCX168, as a candidate for clinical development. The acceptance of the molecule as a development candidate triggered a $5.0 million milestone payment from the alliance with GlaxoSmithKline (NYSE: GSK). CCX168 is designed to specifically target...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related